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I-73 Salvage antiretroviral regimens in resource limited
settings
C.K.C. Lee*. Infectious Diseases Unit, Hospital Sungai
Buloh, Malaysia
The HIV pandemic continues to rage with an estimated
33 million people living with HIV globally by December 2007
and with a staggering 2.5 million new infections in 2007
alone. Countries in the frontline of the disease continue
to struggle with the increasing human and social burden of
this disease which in turn has become a major threat to
country development and growth. On the upside, the world
has seen major advances in HIV medicine esp. in the use of
antiretroviral (ARV) agents in recent years. This has been
mainly due to the development of new therapeutic agents
including better formulations of the older products (eg. heat
stable lopinavir and enteric coated didanosine) as well as
new agents in the established ARV classes eg. new protease
inhibitors, which generally have some advantage over the
earlier compounds (atazanavir, darunavir, etc). While these
have all led to signiﬁcant improvements in patient outcome
either by way of improving adherence (by decreasing pill
burden, improving convenience, improved adverse event
proﬁles, etc) or improved potency towards drug resistant
viral populations ie. agents with different resistant mutation
proﬁles, the major cause for the heightened optimism in HIV
treatment is the rapid development and approval of new
ARV drug classes including the fusion inhibitors, integrase
inhibitors and most recently the CCR5 chemokine receptor
antagonist. All these agents have signiﬁcantly improved
patient outcomes in the developed world esp. with regards
to the improved capability to put together potent 2nd. and
3rd. line ARV regimens. Despite these major advancements,
new challenges do remain with regards to the need for
more clinical data esp. on how best to use these agents in
the real world setting, how they should be best combined,
monitoring of new potential adverse events, etc. The other
major challenge is the ever persistent issue of equitable
access. While ﬁrst line ARV agents are available in most
3rd. world countries (with varying levels of access), 2nd.
line options are generally poor in the developing and less
developed world. Intelligent sequencing of various ARV
regimens, so as to ensure potent and well tolerated 1st.
line regimens and at the same time having effective salvage
regimens in reserve, remains integral in the successful
management of HIV infection. Effective salvage regimens
would depend greatly on a sound understanding of HIV
viral mutation as well as the availability of tools (eg. viral
resistance assays) to assist in ARV selection.
I-74 Practice guidelines for the management of patients
with AIDS and cryptococcal meningitis
H.Z. Lu1,2,3 *. 1Department of Infectious Diseases, Shanghai
Public Health Clinical Center afﬁliated to Fudan university,
201508, 2Huashan hospital afﬁliated to Fudan university,
200040, 3Internal Medicine, Shanghai Medical College of
Fudan university, 200032, China
Cryptococcus neoformans is the most common cause of
fungal meningitis worldwide. Cryptococcal meningitis is a
common opportunistic infection and AIDS deﬁning illness
in patients with late-stage HIV infection. The mortality
of cryptococcosis meningitis in AIDS patients is still high.
Treatment of AIDS patients with cryptococcosis meningitis
should be timely, reasonable and effective. However,
authoritative guideline of this scope for reference is
still lacking in China. Shanghai Public Health Clinical
Center is the only AIDS designed hospital in Shanghai
and we had admitted more than 30 AIDS cases
with cryptococcosis meningitis. Combining the clinical
experience and literature, we summarized the principle
of the management of patients with AIDS and cryptococcal
meningitis.
I-75 Speciﬁc T-cell responses to ESAT-6 and CFP-10 in
Chinese HIV positive individuals without active
TB disease. A way to ﬁnd the latent TB infection in
China?
W.H. Lun*. Department of Dermatology and STD/AIDS
Clinic, Beijing Ditan Hospital, Beijing, China
Background: Tuberculosis (TB) is still a major public health
problem around world, especially in China, AIDS epidemic
have make TB infection more complex than that before.
This study is to evaluate TB speciﬁc T-cell responses in
Chinese HIV infected patients without TB disease by using
the recombinant ESAT-6 and CFP-10 protein as stimulus.
Methods: In house IFN-g based ELISPOT assay was used
to detect ESAT-6 and CFP-10 speciﬁc T-cell responses
separately in HIV (+) patients without clinical manifestation
of TB diseases.
Results: ESAT-6 speciﬁc T-cell responses were detected in
60 of HIV(+) patients without active TB disease, the median
positive frequency was 19 CPU/106 PBMC (inter-quartile
range from 10 51 5 to 51), 14 of 60 patients (23.3%) show
relatively high frequencies (more than 50 CPU/106 PBMC) in
HIV(+) patients without clinical TB diseases. Similarly, CFP-
10 speciﬁc T-cell responses were detected in 73 of HIV(+)
patients without active TB disease, the median positive
frequency was 17 SFC/106 PBMC (inter-quartile range from
5 to 51), 18 of 73 patients (24.7%) show relatively high
frequencies (more than 50CPU/106 PBMC) in HIV(+) patients
without clinical TB diseases.
Conclusions: This was a pilot study for IFN-g based ELISPOT
assay by using recombinant ESAT-6 and CFP-10 protein as
stimulus to detect TB speciﬁc T-cell responses in Chinese HIV
(+) individuals without active TB disease, the high positive
frequency of T-cell responses were detected in more than
23% of this population, further longitudinal assessment is
needed to observe if those positive responses to ESAT-6 and
CFP-10 are related to latent TB infection in Chinese HIV (+)
population.
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I-76 New paradigms for the treatment of hepatitis B
M. Sherman*. University Health Network, Toronto,
Canada
Selection of patients for therapy: There is now good
evidence that the best predictive factor for the
development of cirrhosis and hepatocellular carcinoma is
serum HBVDNA concentration. The higher the HBVDNA
concentration, the higher the risk of HCC. Therefore the
viral load is a major factor in determining whether a
patient should be treated. Normal ALT does not exclude that
advanced ﬁbrosis or cirrhosis might be present. Therefore
normal ALT is not a reason to exclude patients from
treatment.
Therefore, patients who need treatment for hepatitis B are
those who have a viral load greater than 4 5 log copies/ml
and evidence of liver injury. This might be in the form of
persistently elevated ALT, or if the ALT is normal, includes a
liver biopsy. However, if the biopsy shows regressed ﬁbrosis
this should be taken as evidence of more advanced liver
disease.
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Choice of therapy: Patients should be treated with the
most potent antiviral agent available. This is to ensure
maximal suppression of viral replication. A viral load of less
than about 50,000 copies is usually sufﬁcient to prevent
progression of disease. However, in order to prevent the
development of antiviral resistance the target viral load
should be undetectable. Using lamivudine or telbivudine
viral loads greater than about 200 copies/ml 6 months
after starting treatment indicates inadequate response, and
should be a reason to change treatment. With the more
potent agents this is less important.
Duration of therapy: Patients who are positive for HBeAg
should be treated until 6 12 months after seroconversion.
However, since remission may not be durable these
patients should be monitored indeﬁnitely after stopping
therapy. Patients who are anti-HBe-positive need treatment
indeﬁnitely
Combination therapy: As yet there is no data on the use
of combination therapy as ﬁrst line treatment. Possible
combinations include one of lamivudine, telbivudine, or
entecavir with either adefovir or tenofovir. Lamivudine
telbivudine and entecavir should not be used together.
Tenofovir and adefovir should not be used together. Truvada
is the combination of emtricitabine and tenofovir in a single
tablet. Emtricitabine is very similar to lamivudine.
Treatment of antiviral resistance: Patients should be
monitored frequently so that if resistance develops it can
be caught early. Early treatment of antiviral resistance is
more effective than treating resistance one ALT elevation
has occurred. Resistance is deﬁned as more than a 1 log
increase in viral load assuming good compliance.
Resistance to lamivudine or telbivudine is treated
conventionally by adding adefovir. Addition of a second
drug is more effective that switching to a second drug.
Adefovir, but tenofovir will probably be a better choice in
future. It is not known whether tenofovir will require to be
used in combination or not. Since patients who develop
antiviral resistance to more than one agent have very
few if any further options and argument can be made for
treating these patients with a combination of tenofovir and
entecavir. Resistance to entecavir is treated with adefovir
or tenofovir. Resistance to adefovir or tenofovir should be
treated with entecavir.
Long term monitoring: Patients with chronic hepatitis B
should undergo 6 monthly ultrasound screening for HCC.
Patients with known cirrhosis should also have a gastroscopy
to look for esophageal varices.
I-77 The host immunity response of hepatitis B patients
after adefovir dipivoxil and entecavir therapy
Y.F. Jiang, J.Q. Niu*. Department of Infectious Disease,
First Hospital, Jilin University, Changchun 130021, China
Background and Aim: Chronic hepatitis B (CHB) is
thought to involve aberrant immune tolerance of unknown
mechanism. In this study, the immune modulatory effect of
adefovir dipivoxil (ADV) and Entecavir (ETV) was determined
in CHB patients who are positive for hepatitis B e antigen
(HBeAg) based on the efﬁcacy and safety of the Phase IV,
randomized controlled trial result.
Methods: 56 CHB patients were treated with ADV or ETV
and 24 healthy subjects were used as a control. Two classes
of cytokines including IL-2, IFN-g, TNF-a, IL-4, IL-6, IL-10
and regulatory T cells (Tregs), CD4 and CD8 were measured
before treatment and at 12, 24, 36 and 48 weeks after
treatment using a three-color ﬂow cytometry. Samples were
also tested for HBVDNA, ALT and AST.
Results: In patients treated with ADV or ETV, both Th1
and Th2 cytokines were signiﬁcantly increased and found
to be higher than the controls (p < 0.01). The cytokines
production was continuously increased along with treatment
from weeks 12 up to 48. After 24 weeks of treatment,
HBVDNA was greatly reduced among ETV compared to ADV
treatment (p < 0.05), and high production of IL-2, IFN-g,
TNF-a were observed with ETV compared to ADV treatment.
The IFN-g level at weeks 24 and 48 among patients treated
with ETV (16.74±1.34%, 19.78±1.56%) were signiﬁcantly
higher than ADV (7.53±0.55%, 12.56±0.89%) (P< 0.005).
The IL-2 level at weeks 24 and 48 among patients treated
with ETV (10.62±1.11%, 13.14±1.06%) were signiﬁcantly
higher than ADV (5.84±0.46%, 9.46±0.79%) (P< 0.05). The
TNF-a levels at weeks 24 and 48 among patients treated
with ETV (18.35±2.74%, 17.32±1.63%) were signiﬁcantly
higher than ADV (9.96±0.87%, 12.32±1.22%) (P< 0.05). Both
the proportion of CD4+CD25high Tregs (3.08%±0.38%) and
CD4+CD25+CD127low/ Tregs (9.05%±0.69%) were showed
a statistically signiﬁcant increase compared to healthy
controls (1.60%±0.66%, p < 0.01), (1.92%±0.16%, p < 0.01).
The Tregs decreased among patients treated with both
nucleot(s)ide analogue after week 12 until the 36 week.
The CD4/CD8 ratio and the percent of CD4 in CHB
were both signiﬁcantly higher than controls (p < 0.001) and
the CD4/CD8 ratio were showed a statistically signiﬁcant
decrease compared to the baseline after 24 weeks. IL-6,
IL-10, Tregs and the percent of CD4 were associated with
HBVDNA levels at week 24, but were independently related
to ALT and AST level.
Conclusion: Antiviral therapy with ADV or ETV can increase
the Th1/Th2 cytokine secretion in patients with chronic
hepatitis B. ETV induced the secretion of IFN-g more than
ADV. The proportion of Tregs decreased after treatment
of nucleot(s)ide analogue. Cytokine and Treg play an active
role not only in modulating effectors of immune response to
HBV infection, but also in inﬂuencing the disease prognosis
in patients with hepatitis B.
I-78 How to manage and prevent drug resistant HBV
M.F. Yuen*. The University of Hong Kong, China
The major limitation of long-term antiviral therapy for
chronic hepatitis B is the emergence of drug resistance
which negates the beneﬁts of therapy. To minimize the
chance of emergence of hepatitis B virus with drug
resistance, antiviral agent(s) with rapid and potent viral
suppression and high genetic barrier should be the
treatment of choice. If an antiviral agent not possessing
these properties is used, early measurement of HBVDNA
levels should be performed to guide the treatment plan in
the subsequent course. Measurement of viral load reduction
at 24 weeks of treatment to aid decision making should be
mandatory for patients who are receiving antiviral agents
with low genetic barrier. Combination therapy for treatment
naı¨ve patients using two antiviral agents belonging to
different groups is associated with a lower chance of
emergence of drug resistance. However, the best choice
of combination therapy associated with an acceptable low
chance of drug resistance is still being eagerly awaited. With
the availability of various antiviral agents from different
groups, drug resistant HBV to a particular antiviral agent
usually remains susceptible to another antiviral agent of
different group. To ensure better control of viral replication
in patients with drug resistance, adding on or switching
to another antiviral agent with no overlapping resistance
proﬁle should be administered as early as possible, e.g. at
the time when genotypic resistance emerges.
